Gujarat Themis Biosyn Ltd
BSE:506879
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gujarat Themis Biosyn Ltd
Cash from Operating Activities
Gujarat Themis Biosyn Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Gujarat Themis Biosyn Ltd
BSE:506879
|
Cash from Operating Activities
₹710.4m
|
CAGR 3-Years
33%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹58.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹42.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹127.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Operating Activities
₹47.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Operating Activities
₹19.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Gujarat Themis Biosyn Ltd
Glance View
Gujarat Themis Biosyn Ltd. operates as a pharmaceutical company. The company is headquartered in Mumbai, Maharashtra. The firm operates through manufacturing of bulk drugs segment. The firm's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin. The firm's research and development division focuses on developing fermentation cultures. The firm's plant is located at Valsad, Gujarat.
See Also
What is Gujarat Themis Biosyn Ltd's Cash from Operating Activities?
Cash from Operating Activities
710.4m
INR
Based on the financial report for Dec 31, 2025, Gujarat Themis Biosyn Ltd's Cash from Operating Activities amounts to 710.4m INR.
What is Gujarat Themis Biosyn Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
49%
Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for Gujarat Themis Biosyn Ltd have been 33% over the past three years , 49% over the past five years .